PriceTargets.com logo

Armata Pharmaceuticals - ARMP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 161.19%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.68 As of 04/26/2024 02:35 PM ET
▲ +0.15 (5.93%)

This chart shows the closing price for ARMP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Armata Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARMP

Analyst Price Target is $7.00
▲ +161.19% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Armata Pharmaceuticals in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 161.19% upside from the last price of $2.68.

This chart shows the closing price for ARMP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Armata Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$7.00
3/17/2023HC WainwrightReiterated RatingBuy$7.00
3/7/2023HC WainwrightReiterated RatingBuy$7.00
3/22/2021HC WainwrightBoost TargetBuy$5.00 ➝ $7.00
8/14/2020Maxim GroupReiterated RatingBuy$8.00
6/22/2020LADENBURG THALM/SH SHReiterated RatingBuy$9.00
6/18/2020Maxim GroupReiterated RatingBuy$8.00
5/16/2020Maxim GroupInitiated CoverageBuy$8.00
5/15/2020HC WainwrightReiterated RatingBuy$9.00 ➝ $5.00
3/20/2020HC WainwrightReiterated RatingBuy$9.50 ➝ $9.00
3/19/2020Maxim GroupReiterated RatingBuy$8.00
3/13/2020Brookline Capital ManagementReiterated RatingBuy
2/6/2020Maxim GroupInitiated CoverageBuy$8.00
1/29/2020HC WainwrightReiterated RatingBuy$9.50
11/13/2019HC WainwrightReiterated RatingBuy$9.50
10/31/2019HC WainwrightReiterated RatingBuy$7.00 ➝ $9.50
8/21/2019LADENBURG THALM/SH SHReiterated RatingBuy$9.00
8/15/2019HC WainwrightReiterated RatingBuy$7.00
7/15/2019LADENBURG THALM/SH SHReiterated RatingBuy$9.00
6/19/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$9.00
5/23/2019HC WainwrightSet TargetBuy$7.00
(Data available from 4/26/2019 forward)

News Sentiment Rating

1.26 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Armata Pharmaceuticals logo
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $2.68
Low: $2.49
High: $2.68

50 Day Range

MA: N/A

52 Week Range

Now: $2.68
Low: $1.07
High: $5.26

Volume

6,527 shs

Average Volume

16,939 shs

Market Capitalization

$96.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Armata Pharmaceuticals?

The following equities research analysts have issued research reports on Armata Pharmaceuticals in the last year: HC Wainwright.
View the latest analyst ratings for ARMP.

What is the current price target for Armata Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Armata Pharmaceuticals in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 176.6%. HC Wainwright has the highest price target set, predicting ARMP will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Armata Pharmaceuticals in the next year.
View the latest price targets for ARMP.

What is the current consensus analyst rating for Armata Pharmaceuticals?

Armata Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARMP will outperform the market and that investors should add to their positions of Armata Pharmaceuticals.
View the latest ratings for ARMP.

What other companies compete with Armata Pharmaceuticals?

Other companies that are similar to Armata Pharmaceuticals include Curis, Protalix BioTherapeutics, Atara Biotherapeutics, AlloVir and Sangamo Therapeutics. Learn More about companies similar to Armata Pharmaceuticals.

How do I contact Armata Pharmaceuticals' investor relations team?

Armata Pharmaceuticals' physical mailing address is 4503 GLENCOE AVENUE, MARINA DEL REY CA, 90292. The company's listed phone number is (310) 655-2928 and its investor relations email address is [email protected]. The official website for Armata Pharmaceuticals is www.armatapharma.com. Learn More about contacing Armata Pharmaceuticals investor relations.